Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAD+ enhanced mesenchymal stromal cells
- Development stage
- Preclinical
- Lead developer
- Shandong University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
NAD+ enhanced mesenchymal stromal cells (NAD+-MSCs) are an experimental cell therapy consisting of mesenchymal stromal cells (MSCs) pretreated with nicotinamide adenine dinucleotide (NAD+). This pretreatment is designed to overcome the limitations of standard MSCs, such as replicative senescence and reduced activity in the host environment. The mechanism involves the promotion of NAMPT (Nicotinamide phosphoribosyltransferase) secretion by the MSCs, which subsequently activates the SIRT1/PGC-1α signaling pathway in target tissues. This activation improves mitochondrial function and fatty acid oxidation, specifically in skeletal muscle. Research indicates that NAD+-MSCs significantly improve muscle strength, endurance, and mass in models of age-related muscle atrophy (sarcopenia) compared to untreated MSCs.
- Other names
- NAD+ pretreated mesenchymal stromal cellsnicotinamide adenine dinucleotide enhanced mesenchymal stromal cells
02
Targets
SIRT (Sirtuin family)NAMPTPPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)
Beyond the preview
Go deeper on NAD+ enhanced mesenchymal stromal cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAD+ enhanced mesenchymal stromal cells.